Indegene Ltd Acquires UK-Based Healthcare Entities for £2.7M
Filing Summary
Indegene Ltd, through its wholly owned subsidiary Indegene Healthcare UK Limited, has signed a Share Purchase Agreement to acquire 100% equity in two UK-based companies: DT Associates Research and Consulting Services Limited and Trilogy Writing and Consulting Limited. The total consideration for the acquisition is £2,703,348, with completion expected by March 31, 2026. Both acquisitions are related party transactions conducted at arm’s length. These entities will become wholly owned subsidiaries of Indegene Healthcare UK Limited, enhancing Indegene’s presence in the healthcare sector.
Indegene Ltd, through its wholly owned subsidiary Indegene Healthcare UK Limited, has entered into a Share Purchase Agreement to acquire 100% equity shares in two UK-based companies. The companies involved are DT Associates Research and Consulting Services Limited and Trilogy Writing and Consulting Limited. This acquisition was formalized on March 1, 2026, and both entities will become wholly owned subsidiaries of Indegene Healthcare UK Limited.
The financial terms of the acquisition involve a total cash consideration of £2,703,348. Specifically, the acquisition cost for DT Associates Research and Consulting Services Limited is £2,001,000, while Trilogy Writing and Consulting Limited is valued at £702,348. These transactions are classified as related party transactions but are conducted on an arm’s length basis, with no interest from the promoter or promoter group in the entities being acquired.
DT Associates Research and Consulting Services Limited is engaged in providing analytics, technology, and commercial, medical, regulatory, and safety services to life science and healthcare organizations. Trilogy Writing and Consulting Limited offers writing and training services for the pharmaceutical industry. Both companies are based in London and were incorporated in England and Wales. The acquisition aligns with Indegene’s strategic focus on expanding its service offerings in the healthcare sector.
The acquisition is part of an internal restructuring process. No governmental or regulatory approvals are required for this transaction. The completion of the acquisition is anticipated by March 31, 2026. Upon completion, both companies will cease to be subsidiaries of their respective parent companies and will operate under Indegene Healthcare UK Limited.
Indegene Ltd is a global enterprise focused on delivering solutions to healthcare and life sciences organizations. The company specializes in analytics, technology, and consulting services, aiming to enhance healthcare delivery and outcomes. Indegene continues to expand its global footprint and service capabilities through strategic acquisitions and partnerships.